CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Points - CytoDyn Inc. is a clinical-stage biotechnology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications [1][3] - The company will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York City [1] - Robert E. Hoffman, the Chief Financial Officer, will present on September 10 at 1:30 p.m. EDT, and will be available for one-on-one meetings with registered attendees [2] Company Overview - CytoDyn is dedicated to improving patients' quality of life through therapeutic innovation, focusing on conditions related to cancer, infectious diseases, and autoimmune disorders [3] - The company emphasizes integrity, responsibility, and service in its mission to bring transformative treatments to patients worldwide [3]